Half Year 2025 Hua Medicine Earnings Call Transcript

Aug 28, 2025 / 12:00 AM GMT
Release Date Price: $0.4107

Key Points

Positve
  • Hua Medicine (HKSE:02552) reported a 112% increase in revenue, reaching RMB217 million in the first half of 2025.
  • The company successfully transitioned from an R&D-based organization to a commercialization-focused entity, maintaining sales expenses while doubling revenue.
  • Dorsogliatin, a glucokinase modulator, has shown promising results in restoring gluco homeostasis and reducing diabetes complications.
  • Hua Medicine has a strong patent portfolio covering dorsogliatin and its formulations until 2037, providing a competitive edge.
  • The company is expanding its market presence beyond China, with plans to enter Hong Kong, Macau, and Southeast Asia, targeting a large diabetic population.
Negative
  • Despite revenue growth, Hua Medicine (HKSE:02552) reported a net loss of 59.3% for the first half of 2025.
  • The company faces challenges in scaling up production, as there is only one factory globally producing the API for dorsogliatin.
  • Hua Medicine's expansion into international markets may face regulatory and logistical hurdles, potentially delaying market entry.
  • The company is heavily reliant on the success of dorsogliatin, which could pose a risk if the drug encounters unforeseen issues.
  • There is uncertainty regarding the impact of geopolitical issues on Hua Medicine's plans to expand into the US and European markets.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

2552.HK - Hua Medicine
Half Year 2025 Hua Medicine Earnings Call
Aug 29, 2025 / 12:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
And then major progress at Hua medicine in the first half of 25 and then give you a review for a really strong growth in the next year and then coming years.

For dorsogliatin, we are intended to treat diabetes. And, as you may know, there have been 9 classes of anti-diabetic drugs, including the first one, insulin, and then most recent ones, the GOP ones, DPP4 SGLT2s.

Although those classes of drugs have been on the market for at least 15 years, our diabetes still is a global issue, right? By the most recent report by the International Diabetes Federation. The diabetes patient number increased from 500-ish.

Into 589 million.

With 10.

Very bad disease complications.

And in this case,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot